29 related articles for article (PubMed ID: 10738106)
1. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of a novel transcript of ERCC1 in chemotherapy resistance of ovarian cancer.
Liu J; Zhang L; Mao P; Jiang G; Liu L; Wang J; Yang W; Owusu L; Li W
Oncotarget; 2017 Oct; 8(49):85759-85771. PubMed ID: 29156754
[TBL] [Abstract][Full Text] [Related]
3. An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort.
Smith DH; Christensen IJ; Jensen NF; Markussen B; Müller S; Nielsen HJ; Brünner N; Nielsen KV
BMC Cancer; 2013 Oct; 13():489. PubMed ID: 24144331
[TBL] [Abstract][Full Text] [Related]
4. Cell-type-specific level of DNA nucleotide excision repair in primary human mammary and ovarian epithelial cell cultures.
Latimer JJ; Johnson JM; Miles TD; Dimsdale JM; Edwards RP; Kelley JL; Grant SG
Cell Tissue Res; 2008 Sep; 333(3):461-7. PubMed ID: 18575893
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
7. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Reed E; Dabholkar M; Thornton K; Thompson C; Yu JJ; Bostick-Bruton F
Oncol Rep; 2000; 7(5):1123-8. PubMed ID: 10948350
[TBL] [Abstract][Full Text] [Related]
8. Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Dabholkar M; Thornton K; Vionnet J; Bostick-Bruton F; Yu JJ; Reed E
Biochem Pharmacol; 2000 Dec; 60(11):1611-9. PubMed ID: 11077043
[TBL] [Abstract][Full Text] [Related]
9. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Yu JJ; Bicher A; Ma YK; Bostick-Bruton F; Reed E
Cancer Lett; 2000 Apr; 151(2):127-32. PubMed ID: 10738106
[TBL] [Abstract][Full Text] [Related]
10. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
11. Xeroderma pigmentosum and molecular cloning of DNA repair genes.
Boulikas T
Anticancer Res; 1996; 16(2):693-708. PubMed ID: 8687116
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]